Skip to main content
. 2012 Nov 27;11(2):113–126. doi: 10.2165/11591240-000000000-00000

Fig. 6.

Fig. 6

Study schema for AGILE 1051.[65] bid = twice daily; ECOG PS = Eastern Cooperative Oncology Group Performance Status; mRCC = metastatic renal cell carcinoma; OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria In Solid Tumors.